March 24, 2017 — Facing the reality of not having enough votes to secure its passage, House leadership withdrew the ...

At the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17), Philips showcased a broad range of integrated, patient-centric solutions designed to address the prevention, diagnosis, minimally invasive treatment and chronic care at home of cardiac conditions.

Bleeding complications did not increase for patients with acute coronary syndrome treated with rivaroxaban in addition to an antiplatelet medication compared with patients who received the standard treatment of aspirin plus an antiplatelet drug, according to new research. The research was presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low dose ...

In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when given on top of effective statin therapy, had widely varying effects on LDL cholesterol levels and had no benefit on cardiovascular events among those with LDL lower than 100 mg/dL. However, in patients at high cardiovascular risk who had baseline LDL of greater than 100 mg/dL, bococizumab significantly reduced the risk of cardiovascular events by 21 percent compared with placebo, according to research presented at the American College of Cardiology’s 66th Annual Scientific Session, March 17-19 in Washington, D.C.